Advertisement

Topics

Cambridge Antibody Technology Group plc Company Profile

10:29 EST 12th December 2018 | BioPortfolio

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the characteristics of antibodies both to discover and validate new disease targets and to develop human monoclonal antibodies as new treatments for disease.

Location

The Science Park
Melbourn
Cambridgeshire
SG8 6JJ
United Kingdom

Contact

Phone: +44 (0) 1763 263 233
Fax: +44 (0) 1763 263 413
Email: info@cambridgeantibody.com


News Articles [2009 Associated News Articles listed on BioPortfolio]

Absolute Antibody Opens New Facility to Support Continued Growth of its Recombinant Antibody Technology

Absolute Antibody Ltd., specialists in antibody sequencing, engineering and recombinant expression with a vision to make recombinant antibody technology accessible to all, has announced the opening of...

$195M+ #Cancer collaboration combines @Roche with antibody technology of Cambridge, MA, #startup GO Therapeutics: http://ow.ly/9D6030m56nS 

$195M+ #Cancer collaboration combines @Roche with antibody technology of Cambridge, MA, #startup GO Therapeutics: http://ow.ly/9D6030m56nS 

#jobs #lifescience CK Group: Scientific & Project Manager – Cambridge

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CK Group: Scientific & Project Manager – Cambridge . Up to £24.65...

#jobs #lifescience CK Group: Medical Information Contractor – Cambridge

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CK Group: Medical Information Contractor – Cambridge . Very competitive...

IONTAS Celebrates 5 Years of Antibody Discovery

Attributes ongoing success to scientific ethos, project management, and innovative research programs IONTAS Limited (IONTAS), a leader in the discovery and optimisation of ...

Roche, GO Therapeutics to Develop Antibody-Based Cancer Treatments

Roche plans to develop new cancer treatments based on antibody technology for which it has secured an exclusive worldwide license from GO Therapeutics, under a collaboration that the Cambridge, MA, st...

Cambridge Enterprise: How Apollo Therapeutics is driving forward therapeutic innovation.

Iain Thomas, Head of Life Sciences at Cambridge University’s technology transfer arm, discusses the recent launch of Apollo Therapeutics, an ambitious collaboration between AstraZeneca, GlaxoSmithK...

Cambridge Bancorp Announces Record Quarterly Earnings and Declares Dividend

CAMBRIDGE, Mass., Oct. 15, 2018 /PRNewswire/ -- Cambridge Bancorp (NASDAQ: CATC) (the "Company"), the parent of Cambridge Trust Company, today announced unaudited net income of Read more...

PubMed Articles [3734 Associated PubMed Articles listed on BioPortfolio]

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.

The antibody drug market is rapidly expanding, and various antibody engineering technologies are being developed to create antibodies that can provide better benefit to patients. Although bispecific a...

The Effect of Concurrent Tetanus-diphtheria Vaccination on the Antibody Response to Rabies Vaccine: A Preliminary Study.

The number of studies in the literature investigating the effect of tetanus vaccination on rabies prophylaxis is rather limited. In this study, we aimed to investigate the effect of concurrent tetanus...

The Cambridge Social History of Modern Ireland : Edited by E.F. Biagini and M.E. Daly, Cambridge, United Kingdom and New York, NY: Cambridge University Press, 2017.

Engineering therapeutic bispecific antibodies using CrossMab technology.

Bispecific antibodies have recently gained major interest as they allow novel mechanisms-of-action and/or therapeutic applications that cannot be achieved using conventional IgG-based antibodies. A ma...

Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.

To compare the preventive effect of tumor necrosis factor (TNF) inhibitors (anti-TNF antibody and soluble TNF receptor fusion protein (TNFR)) and nonsteroidal anti-inflammatory drugs (NSAIDs) on uveit...

Clinical Trials [7444 Associated Clinical Trials listed on BioPortfolio]

Weight Loss for Obese Individuals With Gout

This study evaluates effect of weight loss in a group of obese patients with gouty arthritis. The study is a randomised group trial where half the patients receive intensive weight loss in...

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

App-technology to Improve Healthy Lifestyle Behaviors Among Working Adults

The aim of this study is to evaluate if modern technology such as smartphone applications can be used to facilitate lifestyle changes and thereby improve health-related quality of life in ...

Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.

Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in mothers and their infants at delivery to establish antibody levels associated with reductions in ...

A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine

This study looks at the body's immune responses to a GBS vaccine 2 years after the orginal vaccine(s) were given in the V98P1 study. Blood will be drawn and evaluated for GBS antibody lev...

Companies [3206 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

The Cambridge Group

The Cambridge Group (http://www.thecambridgegroup.com) is a strategy consulting firm focused on the development of growth strategies for Fortune 500 companies. For over 30 years, The Cambridge Gr...

More Information about "Cambridge Antibody Technology Group plc" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology Group plc news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Group plc Clinical Trials and PubMed Articles about Cambridge Antibody Technology Group plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Group plc Companies in our database. You can also find out about relevant Cambridge Antibody Technology Group plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record